Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Investigates 'Different Pricing Options' Following CHMP Nod For 'Bubble Boy' Gene Therapy

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline PLC's 'bubble boy' treatment has been given a positive opinion by the European Medicines Agency's advisory committee.

You may also be interested in...



Genespire Glides Into Gene Therapy Space

Milan, Italy is a hotspot in Europe for gene therapy research, and the European VC Sofinnova Partners is backing the latest start-up aimed at metabolic and primary immunodeficiencies.

VC Roundup: Magenta Raises $48.5m To Improve Stem Cell Transplants

The Atlas and Third Rock-backed startup Magenta raised a $48.5m Series A round to develop drugs that improve three key steps in the stem cell transplant process. Turnstone, Glycomine and Syntimmune also brought in a combined $61.4m new funding during the first half of November.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

UsernamePublicRestriction

Register

ID1131437

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel